Cutia Therapeutics reported its results for the six months ended 30 June 2025, with revenue decreasing 30.6% year-on-year to RMB66.3 million, compared to RMB95.6 million for the same period in 2024. The company attributed the decline primarily to the termination of its agency cooperation with US skincare brand Phyto-C, influenced by macroeconomic policies and international environmental factors. Resources were reallocated to support commercialization preparations for newly approved products, including CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), which the company projects to have greater market potential and higher return on investment. Net loss for the period narrowed by approximately 19.1% from a loss of RMB200.9 million for the six months ended 30 June 2024. Cutia Therapeutics emphasized its continued commitment to commercializing its new dermatology treatment products in the second half of 2025. The company reported no significant events affecting the group after the reporting period and up to the date of the report.